HHS Announces First 10 Drugs Eligible for Medicare Price Negotiations

CMS headquarters
CMS issued the final rule to implement a $9 billion lump sum payment to 340B hospitals for previous illegal cuts between 2018 and 2021.
The Department of Health and Human Services (HHS) today announced the first 10 prescription drugs eligible for Medicare price negotiations [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

AstraZeneca Sues to Block Medicare Price Negotiations Over ‘Unintended Consequences’ to Orphan Drug Development

AstraZeneca headquarters
The state of Louisiana and a coalition of community health centers urged a federal district court to dismiss AstraZeneca's lawsuit against a state contract pharmacy law.
Drugmaker AstraZeneca sued the federal government to block Medicare drug price negotiations on Friday, just days before the government announced [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Health Center Leaders Urge Boards to Push State, Federal Support of 340B

CHI Expo
The National Association of Community Health Centers’ CHI and Expo addressed the advocacy role of health center boards of directors.
The boards of directors of health centers need to take on a bigger advocacy role in support of the 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B INDUSTRY LEADER SPOTLIGHT

Liz Trenkel, Senior Compliance Specialist, RPh Innovations

Liz Trenkel
Liz Trenkel

Q: Where did you grow up?

In the small town of Vale, Oregon. I now live outside of Chicago, Illinois.

Q: Where did you go to college?

I

Read More »

Health Center Asks Court to Reject Drug Maker Briefs in Challenge to 340B Patient Definition

Genesis
Genesis Health Care successfully challenged HRSA's 340B patient definition in the U.S. District Court for the District of South Carolina.
A health center challenging the government’s 340B program patient definition in a federal district court recently asked a federal judge [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

AHA Urges Dropping Bill Language to Exclude Generic Injectables from 340B

American Hospital Association logo
The American Hospital Association opposed parts of draft legislation from the House E&C Committee concerning the 340B program.
The nation’s largest hospital advocacy organization urged legislators to drop a provision from draft legislation that would exclude generic injectables [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Provider-PhRMA Coalition Adds Civil Rights Group

ASAP 340B
ASAP 340B, a coalition of a drug industry trade group and a community health center organization, added a civil rights group to its membership.
An alliance led by a powerful drug industry trade group and community health center organization that is pushing for 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

From the Publisher & CEO: The Big Question on the Minds of Every 340B Stakeholder

DC court of appeals
340B stakeholders are anticipating two major contract pharmacy judicial rulings, including one from the Court of Appeals for the District of Columbia.
Amid nationwide uncertainty over both the legality of the scope of the 340B contract pharmacy program and the legality of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Federal Appeals Court Schedules Arguments in Challenge to Arkansas Contract Pharmacy Law

340B state legislation map
Two states have laws protecting 340B contract pharmacy arrangements and two others have passed 340B reporting requirements.
A federal appeals court has scheduled oral arguments for September in a case challenging Arkansas’ protections for 340B providers’ contract [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Drug Maker Owes 340B Providers Repayment, HRSA Pending Audit Finds

Nephron Pharmaceuticals
A HRSA fiscal year 2023 audit tentatively found that drug maker Nephron Pharmaceuticals owes 340B repayments to providers.
The first posted fiscal year 2023 audit of a drug maker tentatively found the company owes repayments to providers. The [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report